Canadian researchers are re-evaluating the effectiveness of Paxlovid, a drug once hailed as a key weapon against COVID-19. A new study suggests that while the antiviral medication does not significantly reduce hospitalizations or deaths, it may help patients recover more quickly from the illness.
Study Findings
The research, conducted by a team of scientists across Canada, analyzed data from thousands of patients treated with Paxlovid during the pandemic. The results indicate that the drug did not lower the risk of severe outcomes such as hospital admission or mortality. However, those who took Paxlovid reported faster symptom resolution and a shorter duration of illness.
Implications for Treatment
Dr. Emily Chen, lead author of the study, explained that the findings could shift how doctors prescribe Paxlovid. “While it may not prevent the worst outcomes, it can still be valuable for reducing the burden of illness and helping people return to normal life sooner,” she said. The drug is currently authorized for use in high-risk patients.
Context and Reactions
The study comes as health officials continue to monitor COVID-19 treatments. Some experts argue that even modest benefits are worthwhile, especially for those with mild to moderate symptoms. Others caution that the high cost and potential side effects must be weighed against the limited impact on hospitalization rates.
The research team plans to conduct further studies to identify which patient groups might benefit most from Paxlovid. The findings have been submitted for peer review and are expected to influence future treatment guidelines.
